ACCESSWIRE

The newsfeed available here is provided by our content partner ACCESSWIRE. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.

The NewsWire Hub ("X-Billboard") currently comprises five of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and form a complementary information offering that covers more than three quarters of the official news sources on which editorial offices worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 4.891 Notifications successully processed since Inception

ACCESSWIRE is an important news source for private investors, investors and traders that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market players in one central location. If you want to get a quick overview, you can easily scroll through the headlines. Those who want to take a closer look at the news can use the detailed views of the info cards to directly access the respective news item and other analysis tools.

NEWS
EXPLORER
DE0005664809
State: 21.12.2024 | 3PM
Do you already know our new terminal view? Click here.
FIGI: BBG000C23BS3
EVT
Evotec SE
GICS: 35203010 · Sector: Brain drugs · Sub-Sector: -
NAME
Evotec SE
ISIN
DE0005664809
TICKER
EVT
MIC
XETR
REUTERS
EVTG.DE
BLOOMBERG
EVT GR
Wed, 11.12.2024       Evotec
DE0005664809

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Fri, 29.11.2024       Evotec
DE0005664809

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Fri, 22.11.2024       Evotec
DE0005664809

HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO)Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ:EVO...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Thu, 14.11.2024       Evotec
DE0005664809

HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotec...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Wed, 06.11.2024       Evotec
DE0005664809

Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.11.2024       Evotec
DE0005664809

Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum PartnersTransaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth driversNew ownership committed to maintaining and growing the business HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt St...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Wed, 30.10.2024       Evotec
DE0005664809

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on ...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Wed, 23.10.2024       Evotec
DE0005664809

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncologyEvotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Thu, 26.09.2024       Evotec
DE0005664809

Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technolog...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink
Fri, 20.09.2024       Evotec
DE0005664809

J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the regionJust - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutionsHAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 2...
Read More
Evotec
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the international investor community, we would like to thank AccessWire for providing the news and data feeds